CD86 and breast cancer: Furthermore, we further analysis the correlation of risk score and immune checkpoint in breast cancer and demonstrated that most of key checkpoint were significantly differentially expressed between the two groups in breast cancer patients, including CD44, TIGIT, CTLA4, CD274, CD86 and CD80 (Figure 5D).